CGTN: Super Virus – COVID-19: How We Got Here
11.6.2020 18:12:00 EEST | Business Wire | Press release
The novel coronavirus has so far claimed over 400,000 lives worldwide, according to John Hopkins University. No one knows how dangerous the virus really is and how long the pandemic will last.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200611005636/en/
Super Virus COVID-19 (Photo: Business Wire)
To present readers with a clear picture of how we got here, CGTN portrayed seven* hard-hit countries in an interactive Super Virus. These countries – China, South Korea, the U.S., Germany, France, Italy and the UK – all reported initial confirmed cases at an early stage of the outbreak and all have their relatively mature healthcare systems strained in the fight against it. But their different policy measures have resulted in varied outcomes.
While it’s far too early to draw simple conclusions, the policy measures taken in each country do require scrutiny. The interactive takes a comparative approach in visualizing when and how quickly these measures were enacted over the course of the pandemic. CGTN compiled and analyzed data in the realms of testing, which is crucial to early detection, preventive measures including economic shutdowns and cancellation of public gatherings, as well as the development of clinical methods and the ultimate panacea – an effective vaccine.
Actions taken by countries in regards to testing in the early days appear to have contributed to huge differences down the road. Italy started out with mass testing but then scaled back to only focus on patients who were symptomatic. As the outbreak worsened in Britain, it focused testing and medical resources on critically ill patients.
South Korea and the U.S. reported their first coronavirus cases at almost the same time. But their governments’ attitudes toward testing amid the outbreak couldn’t be more different.
A week after South Korea reported its first case, its health department gathered more than 20 pharmaceutical companies to secure a testing method for COVID-19 that was settled upon eight days later. But weeks after the coronavirus landed in the U.S., there continued to be frustration over shortcomings in diagnostic test distribution and flawed test kits. First there was an outcry over the red tape in getting COVID-19 testing kits approved, then came confusion over who could get a test.
As for travel restrictions, border controls of different types were adopted by many of the six countries. Measures ranged from health checks at the airport to travel warnings and restrictions to quarantining returning overseas travelers. A latecomer to border controls, China didn’t implement restrictions until the end of March when global cases had already exploded.
Such a policy came with extreme measures in certain countries. The Trump administration suspended immigration to the U.S. for 60 days in the name of protecting domestic workers as unemployment hit a record high amid the coronavirus. But this policy left numerous families and businesses reeling instead of boosting employment.
Early-stage border controls also contributed to one problem: Most Western countries neglected prevention and control within their borders.
Restrictions on the movement of peoples within national borders were implemented with varying degrees of effectiveness. Most of the six countries, for instance, adopted stay-at-home orders ahead of lockdowns, except China. In the early morning of January 23, over 20 days after the first known cluster of cases was reported, Wuhan launched a severe lockdown, barring all cars, trains, planes in and out, which lasted 76 days.
In Italy, where similar measures were taken in the country’s northern Lombardy and Veneto – that, combined, makes up 30 percent of the Italian economy, residents were subjected to mandatory home quarantines with all non-essential businesses closed. Meanwhile, some of the other countries like the U.S. and the UK skipped imposing mandatory quarantines in the early stages due to various reasons.
COVID-19 caught the whole world off guard, exposing how we are underprepared in the face of a pandemic of such a scale and scope. The virus has grievously overburdened even the world’s best healthcare systems, with all the seven countries suffering from a dearth of medical professionals and supplies. Doctors and nurses continue to face the danger of being infected, and the psychological burden that they may spread the disease to other patients, or lost their jobs when back from the frontline.
The coronavirus is also not an equal offender — it has disproportionately affected historically marginalized populations. Rates of infection and death from the coronavirus are higher for African and Native Americans, who are on average poorer than their white counterparts. When it comes to age, the elderly makes up a sizable portion of all deaths, due to complications from the coronavirus on top of other conditions. Indigenous peoples are also experiencing higher rates of infection than the national averages of the countries they reside in. In Europe, the Roma live in overcrowded shantytowns, making them particularly affected by the outbreak given the lack of sanitary living conditions.
While outbreaks continue in many of these countries with advanced medical development, the future doesn’t seem to be defined by doom and gloom. Since the outbreak began in January, hundreds of universities, pharmaceutical companies and international organizations have participated in some 320 trials looking into various treatments for COVID-19. Given how divisive COVID-19 has been, the immense scale of this endeavor calls for cooperation across nations, organizations and societies. While time is the best asset for a rapidly spreading pandemic, it is not too late to cultivate this spirit of cooperation.
* The mobile version of the interactive only focuses on six countries for optimal user experience.
Original article: https://news.cgtn.com/news/2020-06-09/Super-Virus-COVID-19-How-we-got-here--Ra9s4L7rBC/index.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200611005636/en/
Contact information
Jiang Simin
jiang.simin@cgtn.com
+86 18826553286
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
